Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777591 | 0.95 | ALDH1A1 (0.48) | ALDH1A1POLBUSP2LMNAKDM4E | |
| SCHEMBL16904245 | 0.86 | ALDH1A1 (0.40) | ALDH1A1POLBUSP2LMNAKDM4E | |
| SCHEMBL29224277 | 0.85 | KDM4E (0.47) | ALDH1A1POLBUSP2LMNAKDM4E | |
| SCHEMBL7195274 | 0.83 | NAAA (0.49) | CYP19A1 | |
| SCHEMBL6673706 | 0.81 | POLB (0.46) | ALDH1A1POLBUSP2LMNAKDM4E | |
| SCHEMBL11884677 | 0.80 | NAAA (0.58) | CYP19A1 | |
| SCHEMBL10412697 | 0.80 | KDM4E (0.47) | ALDH1A1POLBUSP2LMNAKDM4E | |
| SCHEMBL3830715 | 0.79 | MAPT (0.47) | ALDH1A1POLBUSP2LMNAKDM4E | |
| SCHEMBL28392032 | 0.77 | KDM4E (0.48) | ALDH1A1POLBUSP2LMNAKDM4E | |
| SCHEMBL28078471 | 0.77 | TLR4 (0.44) | ALDH1A1POLBLMNAKDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4103591-A | — | — | None | — | — | JP | disclosed |
| CN-114729100-B | Blocked polyisocyanate crosslinking agent, process for producing the same and coating composition comprising the same | 巴斯夫涂料有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117550983-A | Synthesis method of 2- (aminomethyl) cyclopentanol | 南通敏言生物医药科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-103183675-A | Phosphodiesterase-4 inhibitor | KBP BIOSCIENCES CO LTD | 2013-07-03 | — | — | CN | disclosed |
| CN-101962320-B | Method for preparing intermediate 1,2-dicarboxylicacid of antidiabetic medicine gliclazide | ANHUI JINDING PHARMACEUTICAL CO LTD | 2013-03-20 | — | — | CN | disclosed |
| CN-101962320-A | Method for preparing intermediate 1,2-dicarboxylicacid of antidiabetic medicine gliclazide | ANHUI JINDING PHARMACEUTICAL CO LTD | 2011-02-02 | — | — | CN | disclosed |
| EP-1397137-B1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | EP | disclosed |
| US-7482372-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| CN-100348571-C | 2-alkoxyl cyclopentyl ester compound, its synthesis method and application | CHINA PETROLEUM & CHEMICAL (CN) | 2007-11-14 | — | — | CN | disclosed |
| CN-1789234-A | 2-alkoxyl cyclopentyl ester compound, its synthesis method and application | CHINA PETROLEUM & CHEMICAL (CN) | 2006-06-21 | — | — | CN | disclosed |
| US-20050171096-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2005-08-04 | — | — | US | disclosed |
| US-6906053-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-6890915-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040209874-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2004-10-21 | — | — | US | disclosed |
| EP-1397137-A4 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1397137-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-10 | — | — | US | disclosed |
| WO-2002096426-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
| JP-H04103591-A | NEW ASYMMETRIC LIGAND | FUJI YAKUHIN KOGYO KK | 1992-04-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209874-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM8 | ALDH1A1 701/4885POLB 2262/4885USP2 1187/4885 |
| US-20050171096-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM9 | ALDH1A1 600/4885POLB 2398/4885USP2 1182/4885 |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM8 | ALDH1A1 701/4885POLB 2262/4885USP2 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.